University Hospital Of Clermont-Ferrand

The University Hospital Of Clermont-Ferrand is active in cardiovascular diseases, vascular medicine, and related analytical and therapeutic techniques. Research here includes aortic stenosis, myocardial infarction, heart failure, thromboembolic events, and pulmonary embolism, with studies aimed at refining treatment choices, improving prevention, and reducing complications in routine care.

• Evaluation of new strategies for transcatheter aortic valve implantation and post-procedure antithrombotic care
• Studies in acute myocardial infarction and prevention of recurrent cardiovascular events
• Research on thromboembolic disease, stroke, and bleeding-risk balance in vascular patients

These trials focus on better decision-making for patients with complex vascular and cardiac conditions, especially where preventing hospitalization, clotting, or bleeding is a major concern.

Another major area at this site is digestive system diseases, including ulcerative colitis, Crohn’s disease, irritable bowel syndrome, colorectal cancer, gastric cancer, and hepatocellular carcinoma. The research aims to improve symptom control, support remission, and test more effective treatment approaches for inflammatory and cancer-related digestive disorders.

• Trials testing therapies for inflammatory bowel disease and long-term disease control
• Studies in colorectal, gastric, and biliary tract cancers to improve treatment effectiveness
• Work on liver disease, including hepatitis B, cirrhosis, and transplant-related complications

At University Hospital Of Clermont-Ferrand, these projects reflect a strong focus on both chronic digestive inflammation and advanced gastrointestinal cancers.

The site has extensive research in hemic and lymphatic diseases, particularly acute leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myelofibrosis. Many studies also examine stem cell transplantation and new immune-based treatments, with the goal of improving survival and reducing relapse in difficult-to-treat blood cancers.

• Trials for acute lymphoblastic leukemia and acute myeloid leukemia in adults and younger patients
• Research in chronic lymphocytic leukemia, follicular lymphoma, mantle cell lymphoma, and peripheral T-cell lymphoma
• Studies of allogeneic and autologous stem cell transplantation to improve outcomes after intensive treatment

This hematology portfolio shows a strong emphasis on both standard care optimization and newer immunotherapy-based approaches.

Research in immune system diseases is also prominent, covering systemic lupus erythematosus, ANCA-associated vasculitis, giant cell arteritis, rheumatoid arthritis, myasthenic and connective tissue disorders, and kidney disease such as lupus nephritis and IgA nephropathy. These trials generally aim to improve disease control, limit organ damage, and support safer long-term management.

• Studies of treatments for vasculitis and relapse prevention in inflammatory disease
• Trials in systemic lupus and lupus nephritis focused on better immune control
• Research on kidney disorders linked to autoimmune disease or transplantation

The department’s work in this area combines immune-modulating therapies with practical questions about maintaining remission and protecting organ function.

There is also broad activity in nervous system diseases and mental disorders, including multiple sclerosis, Parkinson’s disease, amyotrophic lateral sclerosis, migraine, psychosis, and major depressive disorder. The research focus is on easing symptoms, slowing progression, and improving quality of life through better treatment strategies and supportive care.

• Trials in multiple sclerosis examining long-term disease control and treatment decisions
• Studies for Parkinson’s disease, ALS, and essential tremor aimed at symptom and progression management
• Research in psychiatric disorders, including depression and psychosis, to improve clinical outcomes

These studies show a balance between neurological disease modification and patient-centered symptom relief.

At this hospital/clinic site, investigators are also studying respiratory tract diseases, intensive care, and bacterial and viral infections. Areas include pneumonia, acute respiratory distress, hemoptysis, asthma, and hepatitis, with trials designed to improve emergency care, infection control, and treatment effectiveness.

• Studies in ICU patients to improve breathing support and critical care outcomes
• Research on ventilator-associated pneumonia, hospital-acquired infections, and antibiotic use
• Trials addressing asthma, interstitial lung disease, and pulmonary arterial hypertension

These projects reflect a practical focus on high-risk patients who need timely and effective treatment in acute and intensive care settings.

The research landscape also includes a wide range of neoplasms and rare diseases, such as head and neck cancer, lung cancer, breast cancer, melanoma, sarcomas, retinoblastoma, and several uncommon genetic or inflammatory disorders. The purpose of these trials is often to test more effective therapies, improve survival, and expand options for patients with limited standard treatments.

• Trials in solid tumors including colorectal, gastric, pancreatic, and esophageal cancers
• Research in pediatric and adult rare cancers such as medulloblastoma, ependymoma, and osteosarcoma
• Studies for rare immune and genetic conditions where treatment options remain limited

Across oncology, the site supports both common and uncommon cancer research, with a clear focus on better disease control and more personalized care.